Khaliah Guillory, founder of Nap Bar, says she hopes to expand to 30 locations in three years. Photo courtesy Khaliah Guillory

Editor's note: These Houston innovators are making big strides in the fields of neurotechnology, neurodevelopmental diagnosis, and even improving the way we rest and recharge.

For our latest roundup of Innovators to Know, we meet a researcher who is working with teams in Houston and abroad to develop an innovative brain implant; a professor who has created an AI approach to diagnosis; and a local entrepreneur whose brand is poised for major expansion in the coming years.

Jacob Robinson, CEO of Motif Neurotech

Houston startup Motif Neurotech has been selected by the United Kingdom's Advanced Research + Invention Agency (ARIA) to participate in its inaugural Precision Neurotechnologies program. The program aims to develop advanced brain-interfacing technologies for cognitive and psychiatric conditions. Three Rice labs will collaborate with Motif Neurotech to develop Brain Mesh, which is a distributed network of minimally invasive implants that can stimulate neural circuits and stream neural data in real time. The project has been awarded approximately $5.9 million.

Motif Neurotech was spun out of the Rice lab of Jacob Robinson, a professor of electrical and computer engineering and bioengineering and CEO of Motif Neurotech.

Robinson will lead the system and network integration and encapsulation efforts for Mesh Points implants. According to Rice, these implants, about the size of a grain of rice, will track and modulate brain states and be embedded in the skull through relatively low-risk surgery. Learn more.

Dr. Ryan S. Dhindsa, Dhindsa Lab

Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and his team have developed an artificial intelligence-based approach that will help doctors to identify genes tied to neurodevelopmental disorders. Their research was recently published the American Journal of Human Genetics.

Dhindsa Lab uses “human genomics, human stem cell models, and computational biology to advance precision medicine.” The diagnoses that stem from the new computational tool could include specific types of autism spectrum disorder, epilepsy and developmental delay, disorders that often don’t come with a genetic diagnosis.

“Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered,” Dhindsa says. Learn more.

Khaliah Guillory, Founder of Nap Bar

From nap research to diversity and inclusion, this entrepreneur is making Houston workers more productiveFrom opening Nap Bar and consulting corporations on diversity and inclusion to serving the city as an LGBT adviser, Khaliah Guillory is focused on productivity. Courtesy of Khaliah Guillory

Khalia Guillory launched her white-glove, eco-friendly rest sanctuary business, Nap Bar, in Houston in 2019 to offer a unique rest experience with artificial intelligence integration for working professionals, entrepreneurs and travelers who needed a place to rest, recharge and rejuvenate.

Now she is ready to take it to the next level, with a pivot to VR and plans to expand to 30 locations in three years.

Guillory says she’s now looking to scale the business by partnering with like-minded investors with experience in the wellness space. She envisions locations at national and international airports, which she says offer ripe scenarios for patrons needing to recharge. Additionally, Guillory wants to build on her initial partnership with UT Health by going onsite to curate rest experiences for patients, caregivers, faculty, staff, nurses and doctors. Colleges also offer an opportunity for growth. Learn more.

Rice researchers will collaborate with Houston health tech startup Motif Neurotech to develop Brain Mesh, a distributed network of minimally invasive implants in the skull. Photo via Motif Neurotech

Houston startup, researchers awarded millions to develop Brain Mesh implant

brain health

Houston startup Motif Neurotech and several Rice research groups have been selected by the United Kingdom's Advanced Research + Invention Agency (ARIA) to participate in its inaugural Precision Neurotechnologies program. The program aims to develop advanced brain-interfacing technologies for cognitive and psychiatric conditions.

ARIA will invest $84.2 million over four years in projects that “explore and unlock new methods to interface with the human brain at the circuit level,” according to a news release.

Three of the four Rice labs will collaborate with Houston health tech startup Motif Neurotech to develop Brain Mesh, which is a distributed network of minimally invasive implants that can stimulate neural circuits and stream neural data in real time. The project has been awarded approximately $5.9 million.

Motif Neurotech was spun out of the Rice lab of Jacob Robinson, a professor of electrical and computer engineering and bioengineering and CEO of Motif Neurotech. It will be developed in collaboration with U.K.-based startup MintNeuro, which will help develop custom integrated circuits that will help to miniaturize the implants, according to a separate release.

Robinson will lead the system and network integration and encapsulation efforts for Mesh Points implants. According to Rice, these implants, about the size of a grain of rice, will track and modulate brain states and be embedded in the skull through relatively low-risk surgery.

The Rice lab of Valentin Dragoi, professor of electrical and computer engineering at Rice and the Rosemary and Daniel J. Harrison III Presidential Distinguished Chair in Neuroprosthetics at Houston Methodist, will conduct non-human primate experimental models for Brain Mesh. Kaiyuan Yang, associate professor of electrical and computer engineering who leads the Secure and Intelligent Micro-Systems Lab at Rice, will work on power and data pipeline development to enable the functional miniaturization of the Mesh Points.

“Current neurotechnologies are limited in scale, specificity and compatibility with human use,” Robinson said in a news release. “The Brain Mesh will be a precise, scalable system for brain-state monitoring and modulation across entire neural circuits designed explicitly for human translation. Our team brings together a key set of capabilities and the expertise to not only work through the technical and scientific challenges but also to steward this technology into clinical trials and beyond.”

The fourth Rice lab, led by assistant professor of electrical and computer engineering Jerzy Szablowski, will collaborate with researchers from three universities and two industry partners to develop closed-loop, self-regulating gene therapy for dysfunctional brain circuits. The team is backed by an award of approximately $2.3 million.

“Our goal is to develop a method for returning neural circuits involved in neuropsychiatric illnesses such as epilepsy, schizophrenia, dementia, etc. to normal function and maybe even make them more resilient,” Szablowski said in a news release.

Neurological disorders in the U.K. have a roughly $5.4 billion economic burden, and some estimates run as high as $800 billion annually in terms of economic disruptions in the U.S. These conditions are the leading cause of illness and disability with over one in three people impacted according to the World Health Organization.

Created through the Rice Biotech Launch Pad, Motif Neurotech is focused on developing minimally invasive bioelectronics for the treatment of psychiatric conditions. Photo via motifneuro.tech

Houston mental health tech startup receives industry validation for bioelectronic device

on the right path

A new tool in the fight against treatment-resistant depression could be on the horizon thanks to a Rice University professor.

Jacob Robinson, a professor of electrical and computer engineering and of bioengineering is also co-founder and CEO of Motif Neurotech. Created through the Rice Biotech Launch Pad, Motif Neurotech is focused on developing minimally invasive bioelectronics for the treatment of psychiatric conditions. The company closed its series A round with an oversubscribed $18.75 million earlier this year.

This week, Rice University announced that Robinson has published a peer-reviewed study in Science Advances describing his wireless device called the Digitally programmable Over-brain Therapeutic (DOT). The epidural cortical stimulator is 9 millimeters in width, meaning that it’s easily implantable but is powerful enough to send electrical stimulation to the brain through the dura, the membrane that protects the brain and spinal cord.

“It overcomes challenges by using a battery-free and wireless approach to create an implant that can deliver precise and programmable stimulation to the brain, without brain surgery,” Robinson explained in a press release.

Jacob Robinson, a professor of electrical and computer engineering and of bioengineering, is also co-founder and CEO of Motif Neurotech. Photo via motifneuro.tech

The DOT stimulator is intended to send electrical charges meant to provide neuromodulation for mental health woes including not just depression, but also obsessive compulsive disorder and post-traumatic stress disorder. The treatment could be an alternative to transcranial magnetic stimulation (TMS), a technique that has increased in popularity in recent years.

TMS uses pulsed magnetic fields to stimulate the brain. A typical TMS course includes 36 total treatments and can cause headaches. The DOT stimulator can enact the same timing patterns used in TMS, such as the intermittent theta burst stimulation (iTBS) paradigm, which has been noted to improve mood in patients, but can be achieved at home with far greater ease. Implantation takes just 20 minutes.

So far, the DOT stimulator has been implanted in both a human and a pig. In the pig, researchers noted that the electrical stimulation did not cause any damage to the brain or dura. Just as importantly, it showed stable performance for 30 days in inducing motor responses, meaning it can operate on a longer-term basis.

Motif Neurotech was founded along with Kaiyuan Yang and physicians Sunil Sheth and Sameer Sheth. The Rice Biotech Launchpad brings together local researchers like Robinson and his team with a network of industry executives. With their manuscript, entitled “Miniature battery-free epidural cortical stimulators” freshly published on the Science Advances website, big things could be coming for the bioelectronics company and for sufferers of treatment-resistant depression.

Rice team demonstrates miniature brain stimulator in humanswww.youtube.com

Motif Neurotech, which develops minimally invasive bioelectronics for mental health treatment, closed its series A round with an oversubscribed $18.75 million. Photo via Rice.edu

Rice University medical device spinout secures nearly $19M series A

fresh funding

A health tech startup based out of a newly formed accelerator program at Rice University has raised venture funding.

Motif Neurotech closed its series A round with an oversubscribed $18.75 million. The company, which develops minimally invasive bioelectronics for mental health treatment, was formed out of the Rice Biotech Launch Pad that launched last fall.

The round was led by Arboretum Ventures, with participation from new investors KdT Ventures, Satori Neuro, Dolby Family Ventures, re.Mind Capital and existing investors Divergent Capital, TMC Venture Fund, PsyMed Ventures, Empath Ventures and Capital Factory, according to a news release from Rice.

“Minimally invasive bioelectronics are the future of mental health treatment,” Jacob Robinson, CEO and founder of Motif Neurotech, says in the release. “Thirty percent of patients with depression don’t respond to two or more medications, and there is a significant need for additional treatment options that are effective and easily accessible."

The fresh funding will go toward developing the inaugural product, the DOT microstimulator, a wireless, battery-free device that can provide at-home therapy for treatment-resistant depression, or TRD, a major depressive disorder.

“This is a pivotal moment for the company as it closes its Series A in addition to the recent successful completion of the proof-of-concept first-in-human implant of the DOT stimulator device," Tom Shehab, managing partner of Arboretum Ventures, says in the release. "We believe Motif’s device will greatly improve the quality of life for patients who have been diagnosed with difficult to treat mental health disorders, including TRD."

Shehab, along with Amy Kruse, chief investment officer of Satori Neuro, will reportedly join Motif Neurotech's board of directors alongside Anthony Arnold, president and CEO of Sensydia Corporation, and Jacob Robinson, professor of electrical and computer engineering and bioengineering at Rice.

The Rice Biotech Launch Pad was established to take biotech innovations from concept to clinical trials in five years or less. It occupies 15,000 square feet of space on campus and is funded through federal grants and donations.

The Ion has announced the latest companies to move into the hub. Photo courtesy of The Ion

The Ion announces new tenants that have recently moved in, expanded within the hub

moving in

Several organizations — from tech startups to a nonprofit — have moved into the Ion recently to either relocate or expand their presence in Houston.

The Ion District announced new tenants today, bringing the total space leased to 86 percent, according to a news release. The recent additions to the Ion include:

  • Carbon Clean announced its new United States HQ last month. The startup’s technology has captured nearly two million tons of carbon dioxide at almost 50 sites around the world.
  • Cognite is a Norwegian software company for asset-heavy industries that turns industrial data into customer value.
  • OpenStax, a Houston-based nonprofit, is publishing openly licensed college textbooks that are free online and low cost in print.
  • Synopic is a California-based startup that's building next-gen depth-enabled cameras to improve visualization and decision making during medical procedures.
  • Houston-based Motif Neurotech, a medical equipment manufacturing startup, is working to develop minimally invasive electronic solutions for mental health.
  • RedSwan CRE, founded in Houston, is a crowdfunding-style investment platform and marketplace of tokenized commercial real estate.
  • Nauticus Robotics, a marine robotics hardtech and software company, recently went public.
  • Rice University’s Office of Innovation and its Nexus Lab, which is under construction and designed for prototyping and scaling-up technologies, is increasing its presence in the Ion.
  • Also noteworthy is the expanded office of Ara Partners, which first moved into the Ion last year. The Houston-based, global private equity firm is focused on investing in carbon decentralization technology.
  • Dallas-headquartered flexible workspace provider Common Desk announced that it would expand its space by nearly 50 percent at the Ion last December.

“Welcoming this amazing lineup of new tenants, across the breadth of sectors they represent, demonstrates that the Ion is the place to be and do business in Houston,” says Jan E. Odegard, executive director of the Ion, in the news release. “By continuing to fill our space with new innovators across all these different offerings, from all around the globe, we’ve become the home for collisions that will create solutions to the biggest problems facing our world today.

"We pride ourselves on advancing the diverse knowledge, teams, technologies, and products that will propel our world forward. Our inspiring new tenants will do just that,” he continues.

The Ion's grand opening took place just about a year ago, and existing tenants include Chevron, Microsoft, (Schlumberger) SLB Innovation Factori, Houston Methodist. The growing Ion District is home to more than 300 businesses, including corporates, small businesses, startups, and restaurants.

“The Ion continues to see leasing demand from companies that understand the value of a creative and active work environment,” says Bryson Grover, investment manager of real estate development at Rice Management Co. “Companies are choosing Ion District because it offers more than just a solution for space needs. Workers are given the opportunity to experience a sense of community that brings together like-minded individuals and those with different perspectives.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston startups named most innovative in Texas by LexisNexis

report card

Three Houston companies claimed spots on LexisNexis's 10 Most Innovative Startups in Texas report, with two working in the geothermal energy space.

Sage Geosystems claimed the No. 3 spot on the list, and Fervo Energy followed closely behind at No. 5. Fintech unicorn HighRadius rounded out the list of Houston companies at No. 8.

LexisNexis Intellectual Property Solutions compiled the report. It was based on each company's Patent Asset Index, a proprietary metric from LexisNexis that identifies the strength and value of each company’s patent assets based on factors such as patent quality, geographic scope and size of the portfolio.

Houston tied with Austin, each with three companies represented on the list. Caris Life Sciences, a biotechnology company based in Dallas, claimed the top spot with a Patent Asset Index more than 5 times that of its next competitor, Apptronik, an Austin-based AI-powered humanoid robotics company.

“Texas has always been fertile ground for bold entrepreneurs, and these innovative startups carry that tradition forward with strong businesses based on outstanding patent assets,” Marco Richter, senior director of IP analytics and strategy for LexisNexis Intellectual Property Solutions, said in a release. “These companies have proven their innovation by creating the most valuable patent portfolios in a state that’s known for game-changing inventions and cutting-edge technologies.We are pleased to recognize Texas’ most innovative startups for turning their ideas into patented innovations and look forward to watching them scale, disrupt, and thrive on the foundation they’ve laid today.”

This year's list reflects a range in location and industry. Here's the full list of LexisNexis' 10 Most Innovative Startups in Texas, ranked by patent portfolios.

  1. Caris (Dallas)
  2. Apptronik (Austin)
  3. Sage Geosystems (Houston)
  4. HiddenLayer (Austin)
  5. Fervo Energy (Houston)
  6. Plus One Robotics (San Antonio)
  7. Diligent Robotics (Austin)
  8. HighRadius (Houston)
  9. LTK (Dallas)
  10. Eagle Eye Networks (Austin)

Sage Geosystems has partnered on major geothermal projects with the United States Department of Defense's Defense Innovation Unit, the U.S. Air Force and Meta Platforms. Sage's 3-megawatt commercial EarthStore geothermal energy storage facility in Christine, Texas, was expected to be completed by the end of last year.

Fervo Energy fully contracted its flagship 500 MW geothermal development, Cape Station, this spring. Cape Station is currently one of the world’s largest enhanced geothermal systems (EGS) developments, and the station will begin to deliver electricity to the grid in 2026. The company was recently named North American Company of the Year by research and consulting firm Cleantech Group and came in at No. 6 on Time magazine and Statista’s list of America’s Top GreenTech Companies of 2025. It's now considered a unicorn, meaning its valuation as a private company has surpassed $1 billion.

Meanwhile, HighRadius announced earlier this year that it plans to release a fully autonomous finance platform for the "office of the CFO" by 2027. The company reached unicorn status in 2020.

---

This article originally appeared on Energy Capital HTX.

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.